Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Is there any upper limit of volume or shape of a prostate gland which would be a red flag to cytoreduce prior to treatment?
What is the upper limit of size you would consider offering a patient a five fraction regimen?
Answer from: Radiation Oncologist at Community Practice
Astro/aua consensus guidelines based on published data limits to 100cc or less
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This consensus statement is for SBRT
860
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign in or Register to read more
4362
4375
Related Questions
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
Would you treat someone following FLAME protocol for prostate cancer without fiducials if using daily CBCT?
Is REZUM (water vapor thermotherapy for BPH) safe after EBRT?
Would you ever omit or reduce prostate bed radiation in a post-prostatectomy patient who develops recurrence in pelvic LNs?
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
How would you manage sarcomatoid carcinoma of the prostate with poorly differentiated adenocarcinoma that is not amenable to surgery?
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
For recurrent prostate cancer after prostatectomy with soft tissue mass in the prostate fossa, is hypofractionation an option or is standard fractionation recommended?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
This consensus statement is for SBRT